Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | TACR1 | P25103 | 3/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.53 |
| ▸ | USP7 | Q93009 | 4/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195687 | 1.00 | PDE4B (0.56) | PDE4BSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL3195681 | 1.00 | PDE4B (0.56) | PDE4BSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL7826036 | 0.91 | SLC6A2 (0.64) | PDE4BSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL14403275 | 0.89 | RORC (0.56) | PDE4BTACR1RORCUSP7GPR119 | |
| SCHEMBL14498493 | 0.89 | PDE4B (0.69) | PDE4BSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL23699327 | 0.89 | PDE4B (0.69) | PDE4BSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL3193293 | 0.89 | RORC (0.56) | PDE4BTACR1RORCUSP7GPR119 | |
| SCHEMBL21783705 | 0.89 | PDE4B (0.69) | PDE4BSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL21783709 | 0.89 | PDE4B (0.69) | PDE4BSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL1751263 | 0.89 | RORC (0.56) | PDE4BTACR1RORCUSP7GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938276-B2 | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| WO-2016100157-A2 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | PDE4B 1202/4885SLC6A2 454/4885SLC6A4 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.